Pre- emptive treatment by donor lymphocyte infusions has often been effective. This trial has now been abandoned. They all appear to work as well as with bone marrow. A few clinical studies have started and the initial results are encouraging. 1M are now very limited.
Future production is still uncertain.
Despite the success of this antibody for in vitro T cell depletion, we feel it is important to develop protocols using the IgG antibodies which have a better prospect of being made more widely available. The cell dose should be as high as possible. CyA is optional. Prophylactic add-back of donor T cells is not allowed. Patients should be monitored for residual disease by molecular methods if possible.